9-Aminoacridine Inhibits Ribosome Biogenesis and Synergizes with Cytotoxic Drugs to Induce Selective Killing of p53-Deficient Cells
Molecular Biology of the Cell
2017 ASCB Annual Meeting
Common cancer treatments target rapidly dividing cells and do not discriminate between cancer and normal host cells. One approach to mitigating negative side‐effects of cancer treatment is to temporarily arrest cell cycle progression and thus protect normal cells during cytotoxic treatments, a concept called cyclotherapy. We recently proposed that transient inhibition of post‐transcriptional steps of ribosome biogenesis (RBG) can be used to selectively arrest p53‐positive host cells and not p53‐null cancer cells. In this study, we investigated whether cytoprotective RBG inhibition can be achieved through small molecule treatment.
Anikin L, Pestov D. 9-Aminoacridine inhibits ribosome biogenesis and synergizes with cytotoxic drugs to induce selective killing of p53-deficient cells [Conference Abstract P2170]. Molecular Biology of the Cell. 2017 Dec 15;28(26):3727. doi: 10.1091/mbc.E17-10-0618. PMID: 29237772. PMCID: PMC5739290.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, Chemical Actions and Uses Commons, Medicinal Chemistry and Pharmaceutics Commons, Molecular Biology Commons, Neoplasms Commons, Oncology Commons, Toxicology Commons
The complete published abstracts can be found as "Supplemental Materials" at https://www.molbiolcell.org/doi/10.1091/mbc.e17-10-0618